

Guerbet Announces Research Collaboration with Kyushu University Hospital to Evaluate DUOnco™ Pancreas for Early Detection of Pancreatic Lesions

Founded in 1911, Kyushu University is one of Japan's leading research-oriented institutes of higher education, consistently ranking as one of the top ten Japanese universities in the Times Higher Education World University Rankings and the QS World Rankings.

Villepinte France, April 9th, 2025: Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, is pleased to announce a new clinical collaboration with Kyushu University Hospital to assess the performance of DUOnco™ Pancreas, an innovative artificial intelligence (AI) software designed to aid in incidental detection of pancreatic lesions, manufactured by its affiliate Intrasure (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up.

In 2022, a total of 510,992 new cases of pancreatic cancer were reported worldwide, of which 47,627 occurred in Japan. However, for the same year, epidemiological data estimated 467,409 deaths worldwide and 43,265 in Japan, with a survival rate as low as 9%. Japan had both the third-highest incidence and mortality rates.¹

DUOnco™ Pancreas is an AI-based image analysis software designed to help radiologists detect incidental signs of pancreatic cancer on contrast-enhanced CT scans. Detecting these cancers early gives patients a chance to undergo surgery.

Kyushu University Hospital, renowned for its expertise in pancreatic cancer, will conduct a comprehensive evaluation of DUOnco™ Pancreas. The study will analyze a substantial dataset comprising a majority of Japanese patients and early pancreatic cancers.

Professor Ishigami, Principal Investigator at Kyushu University Hospital, expressed enthusiasm about the collaboration, stating:

"When a pancreatic lesion is suspected, a pancreas-focused multiphase CT is usually performed. However, pancreatic cancer can also be detected incidentally at an early stage from single-phase CT scans (e.g., portal phase) originally performed for other reasons. In this respect, we believe this research project has significant value."

Francois Nicolas, SVP Research, Development, Innovation and AI at Guerbet, commented:

"We are extremely honored to collaborate with Kyushu University Hospital, a world-renowned institution in the field of medical research. This collaboration to evaluate DUOnco™ Pancreas is crucial, as it could bring significant advancements in the early detection of pancreatic lesions. By joining forces with such a prestigious partner, we are committed to delivering meaningful innovations that will improve patient outcomes and push the boundaries of diagnostic medicine."

Contact :

Matthieu BRUNEAU - Global corporate communication manager
Email : matthieu.bruneau@guerbet.com
Phone : +33 6 78 83 89 96
WFProm : I25003527 04/2025

This research aligns with the achievements of the Department of Clinical Radiology at Kyushu University Hospital, which has made multiple contributions to improving pancreatic cancer imaging, including the development of an optimized contrast-enhanced CT protocol for pancreatic cancer detection² among other accomplishments³. Additionally, Kyushu University Hospital has contributed to pancreatic cancer research by developing the internationally recognized Fukuoka guidelines for classifying pancreatic lesions⁴, as well as recent advances such as a novel biomarker for early pancreatic cancer screening⁵.

Finally, this research highlights Guerbet's commitment to advancing AI-based diagnostic solutions, after the recent announcements of the CE mark for DUOnco™ Bones⁶ and the obtention of the Breakthrough Device for status DUOnco™ Pancreas from the FDA⁷.

1. World Cancer Research Fund
2. Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography (2009, Ishigami et al)
3. Intravoxel incoherent motion magnetic resonance imaging for assessment of chronic pancreatitis with special focus on its early stage (2020, Fujita et al)
4. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017, Tanaka et al)
5. New Pancreatic Cancer Test Developed by Kyushu University
6. DUOnco™ Bone: First CE marked AI algorithm for automatic detection of bone lesions on CT scan
7. US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco™ Pancreas for early detection of pancreatic lesions

About Guerbet

Guerbet is a global leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual revenue in research and development, with dedicated innovation centers in France and the United States. The company (GBT) is publicly traded on Euronext Paris and reported €841 million in revenue in 2024.

For more information, visit: www.guerbet.com

About Kyushu University Hospital

Kyushu University Hospital, located in Fukuoka City, is one of Japan's leading national university hospitals. With a history spanning over a century, it serves as a central hub for advanced medical care, education, and research in the Kyushu region. The hospital is affiliated with Kyushu University's Faculty of Medical Sciences and Faculty of Dental Science, offering cutting-edge treatments and conducting pioneering research in various medical fields. It is recognized for its contributions to cancer research, particularly in pancreatic cancer, and plays a significant role in developing innovative diagnostic and therapeutic methods.

For more information, visit: www.hosp.kyushu-u.ac.jp/En/

Media Contact:

Matthieu BRUNEAU - Global corporate communication manager
Email : matthieu.bruneau@guerbet.com
Phone : +33 6 78 83 89 96

Contact :

Matthieu BRUNEAU - Global corporate communication manager
Email : matthieu.bruneau@guerbet.com
Phone : +33 6 78 83 89 96
WFProm : I25003527 04/2025